Valiant Laboratories Ltd
Incorporated in 1980, Valiant Laboratories Limited is a pharmaceutical ingredient manufacturing company in India having focuses on manufacturing Paracetamol.[1]
- Market Cap ₹ 629 Cr.
- Current Price ₹ 145
- High / Low ₹ 227 / 139
- Stock P/E 1,849
- Book Value ₹ 54.5
- Dividend Yield 0.00 %
- ROCE -0.29 %
- ROE 0.20 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Earnings include an other income of Rs.9.68 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|
| 182 | 292 | 334 | 182 | |
| 132 | 249 | 299 | 190 | |
| Operating Profit | 50 | 42 | 35 | -8 |
| OPM % | 27% | 15% | 11% | -5% |
| 1 | 2 | 5 | 10 | |
| Interest | 2 | 0 | 0 | 0 |
| Depreciation | 3 | 2 | 2 | 2 |
| Profit before tax | 47 | 42 | 38 | -1 |
| Tax % | 35% | 34% | 24% | 145% |
| 31 | 28 | 29 | 0 | |
| EPS in Rs | 16.89 | 8.91 | 0.08 | |
| Dividend Payout % | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 0% |
| TTM: | -45% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -78% |
| TTM: | -99% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 17% |
| Last Year: | 0% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|
| Equity Capital | 10 | 16 | 33 | 43 |
| Reserves | 78 | 55 | 68 | 193 |
| 1 | 61 | 60 | 60 | |
| 17 | 49 | 52 | 28 | |
| Total Liabilities | 106 | 182 | 213 | 325 |
| 20 | 22 | 30 | 32 | |
| CWIP | 0 | 1 | 0 | 0 |
| Investments | 0 | 0 | 34 | 119 |
| 87 | 158 | 149 | 174 | |
| Total Assets | 106 | 182 | 213 | 325 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|
| 9 | 2 | 23 | 49 | |
| -17 | -12 | -21 | -183 | |
| 11 | 6 | -2 | 136 | |
| Net Cash Flow | 4 | -4 | 0 | 2 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|
| Debtor Days | 85 | 139 | 97 | 92 |
| Inventory Days | 18 | 25 | 17 | 22 |
| Days Payable | 37 | 72 | 62 | 54 |
| Cash Conversion Cycle | 66 | 91 | 52 | 60 |
| Working Capital Days | 103 | 111 | 106 | 173 |
| ROCE % | 38% | 26% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
22h - Newspaper Publication of Standalone and Consolidated Audited Financial Results for the quarter and year ended March 31, 2024.
-
Announcement under Regulation 30 (LODR)-Monitoring Agency Report
2d - Monitoring Agency Report for quarter ended March 31, 2024
- Statement Of Deviation & Variation For Quarter Ended March 31, 2024. 2d
-
Announcement under Regulation 30 (LODR)-Change in Directorate
2d - Appointment of Mr. Mulesh Manilal Savla as Non- Executive Independent Director of the Company.
- Re-Appointment Of Cost Auditor, Internal Auditor And Secretarial Auditor 2d
Annual reports
No data available.
Business Profile[1] The company manufactures a single product, i.e., Paracetamol, which has several applications, like in treatment headache, muscle ache, arthritis, back ache, toothache, cold, and fever. Paracetamol is one of the most commonly taken analgesics worldwide and is recommended as the first-line therapy in pain conditions by the World Health Organization (WHO).